FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149104348> ?p ?o ?g. }

• W2149104348 endingPage "682" @default.
• W2149104348 startingPage "677" @default.
• W2149104348 abstract "In a prospective multicenter phase II study, we evaluated the effect of three courses of vincristine, doxorubicin and dexamethasone followed by high-dose melphalan and autologous stem cell transplantation on an intention-to-treat basis. Sixty-nine newly diagnosed patients with amyloid light chain amyloidosis were included between November 2000 and January 2006: 37 men and 32 women with a median age of 56 years, including 46% of patients with cardiac and 22% of patients with involvement of 3 or 4 organs. Initial results presented in 2008 showed a 4-year overall survival rate of 62% among all the patients, while the 4-year survival rate after transplantation was 78%. Here we report the long-term follow-up data after a median follow up of 115 months of the patients still alive. Median survival of all patients was 96 months from registration and for the transplanted patients ten years from the date of transplantation. Twelve (12%) patients died during induction therapy with vincristine, doxorubicin and dexamethasone, including 8 patients (12%) due to treatment-related mortality. Two patients died within one month following high-dose melphalan. We conclude that vincristine, doxorubicin and dexamethasone should not be applied as induction therapy for intensification in amyloid light chain amyloidosis. However, a 2-step approach consisting of a non-intensive less toxic induction therapy followed by high-dose melphalan and autologous stem cell transplantation may result in extended survival in newly diagnosed patients with amyloid light chain amyloidosis (clinicaltrials.gov identifier: 01207094)." @default.
• W2149104348 created "2016-06-24" @default.
• W2149104348 creator A5002972322 @default.
• W2149104348 creator A5006799794 @default.
• W2149104348 creator A5014521715 @default.
• W2149104348 creator A5015822462 @default.
• W2149104348 creator A5022643534 @default.
• W2149104348 creator A5023165076 @default.
• W2149104348 creator A5035280433 @default.
• W2149104348 creator A5040082277 @default.
• W2149104348 creator A5043494139 @default.
• W2149104348 creator A5045244406 @default.
• W2149104348 creator A5050532707 @default.
• W2149104348 creator A5058429057 @default.
• W2149104348 creator A5073604089 @default.
• W2149104348 creator A5082157943 @default.
• W2149104348 creator A5083385949 @default.
• W2149104348 date "2015-02-06" @default.
• W2149104348 modified "2023-10-09" @default.
• W2149104348 title "Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology" @default.
• W2149104348 cites W1492397565 @default.
• W2149104348 cites W1891153794 @default.
• W2149104348 cites W1963505205 @default.
• W2149104348 cites W1968646226 @default.
• W2149104348 cites W1971828262 @default.
• W2149104348 cites W1973853538 @default.
• W2149104348 cites W1984419711 @default.
• W2149104348 cites W1999473831 @default.
• W2149104348 cites W2017496708 @default.
• W2149104348 cites W2017612047 @default.
• W2149104348 cites W2022248147 @default.
• W2149104348 cites W2022862731 @default.
• W2149104348 cites W2033793452 @default.
• W2149104348 cites W2044266840 @default.
• W2149104348 cites W2058789242 @default.
• W2149104348 cites W2066835856 @default.
• W2149104348 cites W2070335603 @default.
• W2149104348 cites W2080811710 @default.
• W2149104348 cites W2098093182 @default.
• W2149104348 cites W2107403553 @default.
• W2149104348 cites W2111080788 @default.
• W2149104348 cites W2128536827 @default.
• W2149104348 cites W2142368474 @default.
• W2149104348 cites W2144588669 @default.
• W2149104348 cites W2161648900 @default.
• W2149104348 cites W2171552949 @default.
• W2149104348 cites W2330694848 @default.
• W2149104348 doi "https://doi.org/10.3324/haematol.2014.119198" @default.
• W2149104348 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4420217" @default.
• W2149104348 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25661441" @default.
• W2149104348 hasPublicationYear "2015" @default.
• W2149104348 type Work @default.
• W2149104348 sameAs 2149104348 @default.
• W2149104348 citedByCount "15" @default.
• W2149104348 countsByYear W21491043482016 @default.
• W2149104348 countsByYear W21491043482017 @default.
• W2149104348 countsByYear W21491043482018 @default.
• W2149104348 countsByYear W21491043482019 @default.
• W2149104348 countsByYear W21491043482020 @default.
• W2149104348 countsByYear W21491043482022 @default.
• W2149104348 crossrefType "journal-article" @default.
• W2149104348 hasAuthorship W2149104348A5002972322 @default.
• W2149104348 hasAuthorship W2149104348A5006799794 @default.
• W2149104348 hasAuthorship W2149104348A5014521715 @default.
• W2149104348 hasAuthorship W2149104348A5015822462 @default.
• W2149104348 hasAuthorship W2149104348A5022643534 @default.
• W2149104348 hasAuthorship W2149104348A5023165076 @default.
• W2149104348 hasAuthorship W2149104348A5035280433 @default.
• W2149104348 hasAuthorship W2149104348A5040082277 @default.
• W2149104348 hasAuthorship W2149104348A5043494139 @default.
• W2149104348 hasAuthorship W2149104348A5045244406 @default.
• W2149104348 hasAuthorship W2149104348A5050532707 @default.
• W2149104348 hasAuthorship W2149104348A5058429057 @default.
• W2149104348 hasAuthorship W2149104348A5073604089 @default.
• W2149104348 hasAuthorship W2149104348A5082157943 @default.
• W2149104348 hasAuthorship W2149104348A5083385949 @default.
• W2149104348 hasBestOaLocation W21491043481 @default.
• W2149104348 hasConcept C126322002 @default.
• W2149104348 hasConcept C141071460 @default.
• W2149104348 hasConcept C143998085 @default.
• W2149104348 hasConcept C159654299 @default.
• W2149104348 hasConcept C203014093 @default.
• W2149104348 hasConcept C2776694085 @default.
• W2149104348 hasConcept C2776755627 @default.
• W2149104348 hasConcept C2778684742 @default.
• W2149104348 hasConcept C2779050716 @default.
• W2149104348 hasConcept C2779429289 @default.
• W2149104348 hasConcept C2779551797 @default.
• W2149104348 hasConcept C2779951007 @default.
• W2149104348 hasConcept C2780401358 @default.
• W2149104348 hasConcept C2781303535 @default.
• W2149104348 hasConcept C2911091166 @default.
• W2149104348 hasConcept C36394416 @default.
• W2149104348 hasConcept C71924100 @default.
• W2149104348 hasConcept C90924648 @default.
• W2149104348 hasConceptScore W2149104348C126322002 @default.
• W2149104348 hasConceptScore W2149104348C141071460 @default.
• W2149104348 hasConceptScore W2149104348C143998085 @default.

• next